Adelphi Real World, Cheshire, United Kingdom
Robert Wood , Debanjali Mitra , Jonathan De Courcy , Shrividya Iyer
Background: To assess patient reported breast cancer (BC) specific quality of life (QOL) in HR+/HER2- advanced or metastatic BC (ABC/MBC). Methods: Patients (N=2,352) were recruited into a cross-sectional survey from centers in 5 major EU countries and the US. BC specific QOL was reported by a subset of patients (n=739) using the Functional Assessment of Cancer Therapy Breast (FACT-B) tool, which includes the FACT General (FACT-G) (4 subscales assessing physical [PWB], social [SWB], emotional [EWB], and functional [FWB] wellbeing) and the BC specific subscale (BCS). Results are reported for the overall cohort, by therapy and sites of metastases. Significance was assessed using Mann-Whitney U and Kruskal-Wallis tests. Results: Patients’ mean (SD) age was 65.2 (10.6). Most patients (82.7%, n=611) had MBC, of which 31.9% had bone only metastases, 39.6% visceral only, 18.0% had bone + visceral, and 10.5% had other metastasis sites. Most patients received either endocrine or chemotherapy (46.3% and 48.6%), while 3% were on both and 2.2% on neither therapy. Mean (SD) scores for FACT-G and FACT-B were 61.8 (15.8) and 85.9 (19.7) respectively. FACT scores stratified by current therapy and sites of metastases are in the table below. Significantly (p<0.05) better scores were reported in endocrine therapy patients compared to chemotherapy for all subscales. Significantly worse scores were reported in the bone + visceral group for all subscales except for SWB and FWB. Conclusions: Type of therapy and sites of metastases have a significant impact on patient reported BC QOL in HR+/HER2- ABC/MBC.
Current Therapy | Sites of Metastases | ||||
---|---|---|---|---|---|
Endocrine (n=342) | Chemotherapy (n=359) | Bone Only (n=195) | Visceral Only (n=242) | Bone + Visceral (n=110) | |
PWB | 19.9 (5.7) | 18.0 (5.0)* | 19.1 (5.5) | 18.7 (5.5) | 17.1 (5.4)* |
SWB | 17.9 (6.0) | 17.1 (5.2)* | 17.7 (5.8) | 16.9 (5.9) | 17.0 (5.2) |
EWB | 13.7 (4.6) | 12.8 (4.2)* | 13.7 (4.5) | 13.1 (4.6) | 12.0 (4.3)* |
FWB | 13.6 (5.9) | 12.1 (4.8)* | 13.1 (5.8) | 12.5 (5.5) | 11.8 (4.9) |
BCS | 25.2 (5.9) | 23.2 (5.1)* | 25.0 (5.7) | 23.7 (5.6) | 22.2 (5.6)* |
FACT-G Total | 65.0 (17.3) | 59.8 (13.1)* | 63.7 (16.3) | 60.9 (15.8) | 57.7 (15.1)* |
FACT-B Total | 90.4 (21.3) | 83.1 (16.4)* | 88.7 (20.4) | 84.8 (19.4) | 79.7 (18.6)* |
* P<0.05. Visceral = brain, liver, lung, pancreas.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Maria Alice B Franzoi
2024 ASCO Quality Care Symposium
First Author: Erin Aiello Bowles
2023 ASCO Annual Meeting
First Author: Jenna Bhimani
2023 ASCO Annual Meeting
First Author: Tracy Fulton